NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological DisordersAccesswire • Monday
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin DependenceAccesswire • 10/21/24
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing RulesAccesswire • 10/15/24
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share SplitAccesswire • 09/25/24
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease TreatmentsAccesswire • 06/27/24
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing RequirementsAccesswire • 06/25/24
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)Accesswire • 06/11/24
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request HearingAccesswire • 04/19/24
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist PlatformAccesswire • 03/20/24